If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Fat or protein in the food or drink will delay absorption and should be avoided. So a glucose tablet is ideal, a candy bar or pastry is not (both contain fat in addition to starch and usually sugar). Orange juice works, but less well than intended, as its main carbohydrate is fructose. See also: Hypoglycemia; insulin shock. Insulin receptors Protein complexes on the surface of a cell that allows the cell to join or bind with insulin that is in the blood. When the vrll membrane receptor and insulin bind, the cell takes up glucose (sugar) from the blood and can use it for energy. Insulin resistance a condition in which a cell is resistant to insulin action, usually as a result of Type 2 diabetes which is characterized by insulin resistance in about two-thirds of the body's cells (those which require insulin in order to absorb glucose from the blood). The result is that the beta cells can no longer regulate body metabolism correctly. Insulin resistance syndrome A syndrome (set of signs and symptoms) resulting from insulin resistance. It is also called metabolic syndrome. Insulin shock A severe condition that occurs when the level of blood glucose (sugar) drops too far and quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough. In severe cases, brain damage, nerve damage, or even death is possible. Formerly used, in hospitals, as a treatment for some kinds of mental illness. See also: Hypoglycemia; insulin reaction.
=== Technology === Hydrogen easily diffuses through heated palladium, and membrane reactors with Pd membranes are used in the production of high purity hydrogen. Palladium is used in palladium-hydrogen electrodes in electrochemical studies. Palladium(II) chloride readily catalyzes carbon monoxide gas to carbon dioxide and is useful in carbon monoxide detectors. Palladium has been used to produce metallic glass by fast cooling alloys, avoiding their crystallisation, thus reducing brittleness and leading to stronger materials.
Rubidium was discovered in 1861 by Robert Bunsen and Gustav Kirchhoff, in Heidelberg, Germany, in the mineral lepidolite through flame spectroscopy. Because of the bright red lines in its emission spectrum, they chose a name derived from the Latin word rubidus, meaning "deep red". Rubidium is a minor component in lepidolite. Kirchhoff and Bunsen processed 150 kg of a lepidolite containing only 0.24% rubidium monoxide (Rb2O). Both potassium and rubidium form insoluble salts with chloroplatinic acid, but those salts show a slight difference in solubility in hot water. Therefore, the less soluble rubidium hexachloroplatinate (Rb2PtCl6) could be obtained by fractional crystallization. After reduction of the hexachloroplatinate with hydrogen, the process yielded 0.51 grams of rubidium chloride (RbCl) for further studies. Bunsen and Kirchhoff began their first large-scale isolation of caesium and rubidium compounds with 44,000 litres (12,000 US gal) of mineral water, which yielded 7.3 grams of caesium chloride and 9.2 grams of rubidium chloride. Rubidium was the second element, shortly after caesium, to be discovered by spectroscopy, just one year after the invention of the spectroscope by Bunsen and Kirchhoff. The two scientists used the rubidium chloride to estimate that the atomic weight of the new element was 85.36 (the currently accepted value is 85.47).
Benzodiazepines developed in the former Soviet Union (e.g. phenazepam, gidazepam etc.) Benzodiazepines predominantly used only in Japan (e.g. nimetazepam, flutoprazepam etc.) 4,5-cyclised benzodiazepines (e.g. ketazolam, cloxazolam etc.), and other compounds not researched by Roche Benzodiazepines developed more recently (e.g. remimazolam, QH-ii-066, Ro48-6791 etc.) "Designer" benzodiazepines for which in vitro binding data are unavailable (e.g. flubromazolam, pyrazolam etc.) While binding or activity data are available for most of these compounds also, the assay conditions vary between sources, meaning that in many cases the values are not suitable for a direct comparison. Many older sources used animal measures of activity (i.e. sedation or anticonvulsant activity) but did not measure in vitro binding to benzodiazepine receptors. See for instance Table 2 vs Table 11 in the Chem Rev paper, Table 2 lists in vitro pIC50 values matching those below, while Table 11 has pEC50 values derived from in vivo assays in mice, which show the same activity trends but cannot be compared directly, and includes data for compounds such as diclazepam and flubromazepam which are not available in the main data set. Also note;
Sources: en.wikipedia.org
=== Pepper spray and pests === Capsaicinoids are also an active ingredient in riot control and personal defense pepper spray agents. When the spray comes in contact with skin, especially eyes or mucous membranes, it produces pain and breathing difficulty in the affected individual. Capsaicin is also used to deter pests, specifically mammalian pests. Targets of capsaicin repellants include voles, deer, rabbits, squirrels, bears, insects, and attacking dogs. Ground or crushed dried chili pods may be used in birdseed to deter rodents, taking advantage of the insensitivity of birds to capsaicin. The Elephant Pepper Development Trust claims that using chili peppers as a barrier crop can be a sustainable means for rural African farmers to deter elephants from eating their crops. An article published in the Journal of Environmental Science and Health, Part B in 2006 states that "Although hot chili pepper extract is commonly used as a component of household and garden insect-repellent formulas, it is not clear that the capsaicinoid elements of the extract are responsible for its repellency." The first pesticide product using solely capsaicin as the active ingredient was registered with the U.S. Department of Agriculture in 1962.
=== Manufacturer response === Palm oil, a natural oil extracted from the fruit of oil palm trees that is semi-solid at room temperature (15–25 degrees Celsius), can potentially serve as a substitute for partially hydrogenated fats in baking and processed food applications, although there is disagreement about whether replacing partially hydrogenated fats with palm oil confers any health benefits. A 2006 study supported by the National Institutes of Health and the USDA Agricultural Research Service concluded that palm oil is not a safe substitute for partially hydrogenated fats (trans fats) in the food industry, because palm oil results in adverse changes in the blood concentrations of LDL and apolipoprotein B just as trans fat does. In May 2003, BanTransFats.com Inc., a U.S. non-profit corporation, filed a lawsuit against the food manufacturer Kraft Foods in an attempt to force Kraft to remove trans fats from the Oreo cookie. The lawsuit was withdrawn when Kraft agreed to work on ways to find a substitute for the trans fat in the Oreo. The J.M. Smucker Company, then the American manufacturer of Crisco (the original partially hydrogenated vegetable shortening), in 2004 released a new formulation made from solid saturated palm oil cut with soybean oil and sunflower oil. This blend yielded an equivalent shortening much like the prior partially hydrogenated Crisco, and was labelled zero grams of trans fat per 1 tablespoon serving (as compared with 1.5 grams per tablespoon of original Crisco).
Lactic acid bacteria ferments the sugars into lactic acid and yeast makes ethanol, which through aging and secondary fermentation makes numerous flavor compounds typical of soy sauce. Pressing: The fully fermented grain slurry is placed into cloth-lined containers and pressed to separate the solids from the liquid soy sauce. The isolated solids are used as fertilizer or fed to animals while the liquid soy sauce is processed further. Pasteurization: The raw soy sauce is heated to eliminate any active yeasts and molds remaining in the soy sauce and can be filtered to remove any fine particulates. Storage: The soy sauce can be aged or directly bottled and sold.
The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings. (ICH E9) Global assessment variable
===== Historical ===== Spider silk is one of the earliest known dermal patches. Primarily used for wound binding, the glycoprotein adhesive found on the capture spiral silk, as well as the protein structure of the fiber itself, has mild antibacterial properties. The silk, acting as a local antiseptic, reduced the rate of sepsis and chronic illness. The silk's viscoelastic properties and high tensile strength and toughness aided wound healing in a way similar to surgical tape.
Sources: en.wikipedia.org
== Investors == In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. Other Investors include Greenspring Associates, Alta Partners and Granite Venture Partners. In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors. In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650. In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch. In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.
=== Electrode layers and electrolyte === On the macrostructral level (length scale 0.1–5 mm) almost all commercial lithium-ion batteries comprise foil current collectors (aluminium for cathode and copper for anode). Copper is selected for the anode, because lithium does not alloy with it. Aluminum is used for the cathode, because it passivates in LiPF6 electrolytes.
The Unitized Group Ration – Express (UGR-E or UGR-Express), nicknamed the "kitchen in a carton", consists of meals in self-heating steam table trays based on the UGR-H&S meal offerings. The UGR-E is designed to provide hot meals where feeding a group with hot food would otherwise be unfeasible. Unlike other UGRs, it uses a flameless ration heater and does not require a separate field kitchen. The UGR-E begins heating with the pull of a tab, and can fully heat a meal within 30 to 45 minutes. The UGR-E has 4 breakfast menus, 8 lunch/dinner menus, and 1 holiday menu. Each meal provides an average of 1,300 kcal. Each UGR-E module contains 18 meals, with each pallet holding 400 meals. UGR-E modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).
=== Fluorescent detection === Fluorescence spectroscopy is one of the most common droplet detection techniques. It provides a rapid response, and, for applicable analytes, it has a strong signal. The use of fluorescence spectroscopy in microfluidics follows a similar format to most other fluorescent analytical techniques. A light source is used to excite analyte molecules in the sample, after which the analyte fluoresces, and the fluorescence response is the measured output. Cameras can be used to capture the fluorescence signal of the droplets, and filters are often used to filter out scattered excitation light. In microfluidic droplet detection, the experimental setup of a fluorescence instrument can vary greatly. A common setup in fluorescent droplet detection is with the use of an epifluorescence microscope. This sometimes utilizes a confocal geometry, which can vary depending on experimental needs. For example, Jeffries et al. reported success with exploring an orthogonal confocal geometry, as opposed to a standard epi geometry. However, other setups for fluorescence detection have been explored, as epifluorescence microscopes can be expensive and difficult to upkeep. Cole et al. have proposed and tested an experimental setup with fiber optics to conduct fluorescence analysis of microfluidic droplets. Fluorescence detection of droplets has a number of advantages. First, it can accommodate a large and fast throughput. Analysis of thousands of samples can be conducted in a short period of time, which is advantageous for the analysis of a large number of samples.
Additionally, when physicochemical properties or structures are expressed by numbers, one can find a mathematical relationship, or quantitative structure-activity relationship, between the two. The mathematical expression, if carefully validated, can then be used to predict the modeled response of other chemical structures. A QSAR has the form of a mathematical model:
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.